Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social determinants of health in lung cancer surgery: perspectives from family caregivers, clinicians, and healthcare system administrators.

Frontiers in public health·2026
Same author

Interrelationship Between Patient and Family Caregiver Outcomes Following Lung Cancer Surgery: A Secondary Analysis of a Randomized Controlled Trial.

Psycho-oncology·2026
Same author

Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options.

Clinical lung cancer·2025
Same author

Survival and Treatment Patterns in Stage II to III Esophageal Cancer.

JAMA network open·2024
Same author

Geriatric Assessment-driven INterventions among Hospitalized older adults with cancer (GAIN-HOSP), a prospective pilot study.

Journal of geriatric oncology·2024
Same author

Comparative effectiveness of perioperative physical activity in older adults with lung cancer and their family caregivers: design of a multicenter pragmatic randomized trial.

BMC cancer·2024

Related Experiment Video

Updated: Jul 6, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.

Howard Jack West1,2, Jae Y Kim3

  • 1Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California.

JAMA Oncology
|December 28, 2023
PubMed
Summary

New treatments for resectable non-small cell lung cancer (NSCLC) offer improved survival. Adjuvant osimertinib and neoadjuvant chemoimmunotherapy are changing standards of care, but optimal patient selection and treatment sequencing require further study.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

Related Experiment Videos

Last Updated: Jul 6, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Genomic Medicine

Background:

  • Recent clinical trials have significantly altered the standard of care for resectable early-stage non-small cell lung cancer (NSCLC).
  • New adjuvant and neoadjuvant therapies demonstrate improved efficacy, raising questions about clinical application.
  • The evolving landscape necessitates a re-evaluation of treatment strategies for NSCLC.

Approach:

  • Review of recent high-profile clinical trials in resectable NSCLC.
  • Analysis of adjuvant targeted therapy (osimertinib) for EGFR-mutated NSCLC.
  • Evaluation of neoadjuvant chemotherapy with nivolumab and adjuvant immunotherapy (atezolizumab, pembrolizumab).

Key Points:

  • Adjuvant osimertinib significantly improves disease-free survival (DFS) and overall survival (OS) in EGFR-mutated NSCLC.
  • Neoadjuvant chemotherapy with nivolumab shows event-free survival (EFS) benefits.
  • Adjuvant atezolizumab demonstrates OS benefit in PD-L1 high NSCLC; pembrolizumab shows DFS benefits.
  • Perioperative chemoimmunotherapy trials highlight evolving treatment paradigms.

Conclusions:

  • New adjuvant and neoadjuvant therapies represent significant advancements in resectable NSCLC treatment.
  • Clinical judgment and patient discussion are crucial for navigating treatment choices due to evolving data.
  • Further research is needed to optimize sequencing and patient selection for these novel NSCLC therapies.